Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk is planning a new Phase III trial ... Novo said that the trial’s flexible design – meaning that patients could scale their dosing based on side effects – meant that the weight ...

Let's look deeper into these results and what they could mean for investors. Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a ...